Dosimetric verification of stereotactic body radiotherapy treatment plan via ArcCHECK-3DVH system. / ArcCHECK-3DVH系统在体部立体定向放射治疗剂量验证中的应用.

OBJECTIVES: To study the feasibility of ArcCHECK-3DVH system in dosimetric verification for stereotactic body radiaotherapy (SBRT) with flattening filter free (FFF) model. METHODS: SBRT treatment plans for 57 patients were introduced into ArcCHECK phantom and recalculated. The calculated dose distribution of treatment planning system and the measured dose distribution of ArcCHECK phantom were compared by γ analysis. Then the 3 dimensional dose distribution of target and organs at risk was reconstructed by 3DVH software. The reconstructed dose and calculated dose with treatment planning system (TPS) were compared, and the dose volume γ pass rate and deviation of dose volume parameters to the target and organs at risk were quantitatively valuated. RESULTS: Based on the threshold criteria (3%, 3 mm, 10%), namely the deviation of measuring points between the planned value and the measured value was less than 3%, and the proportion of points with similar values in the plane or sphere with the center of the point and the radius of 3 mm was 10%, the relative and absolute dose pass rates of SBRT treatment plans in ArcCHECK system via γ analysis were greater than 95%. Based on the stricter threshold criteria (2%, 2 mm, 10%), the relative and absolute dose pass rates of SBRT treatment plan in ArcCHECK system via γ analysis were about 93%. In 3DVH dose verification, the γ pass rate of target and organs at risk was exceed 97%, and the deviations in 3DVH of the target and organs at risk were less than ±5%. CONCLUSIONS: The ArcCHECK-3DVH system in dose verification can provide more comprehensive dose distribution information to reasonably evaluate the SBRT plan, with more significance for guiding clinical treatment.

Impact of different optimization strategies on the compatibility between planned and delivered doses during radiation therapy of cervical cancer.

PURPOSE: To analyse the impact of different optimization strategies on the compatibility between planned and delivered doses during radiotherapy of cervical cancer. MATERIAL/METHODS: Four treatment plans differing in optimisation strategies were prepared for ten cervical cancer cases. These were: volumetric modulated arc therapy with (_OPT) and without optimization of the doses in the bone marrow and for two sets of margins applied to the clinical target volume that arose from image guidance based on the bones (IG(B)) and soft tissues (IG(ST)). The plans were subjected to dosimetric verification by using the ArcCHECK system and 3DVH software. The planned dose distributions were compared with the corresponding measured dose distributions in the light of complexity of the plans and its deliverability. RESULTS: The clinically significant impact of the plans complexity on their deliverability is visible only for the gamma passing rates analysis performed in a local mode and directly in the organs. While more general analyses show statistically significant differences, the clinical relevance of them has not been confirmed. The analysis showed that IG(ST)_OPT and IG(B)_OPT significantly differ from IG(ST) and IG(B). The clinical acceptance of IG(ST)_OPT obtained for hard combinations of gamma acceptance criteria (2%/2 mm) confirm its satisfactory deliverability. In turn, for IG(B)_OPT in the case of the rectum, the combination of 2%/2 mm did not meet the criteria of acceptance. CONCLUSION: Despite the complexity of the IG(ST)_OPT, the results of analysis confirm the acceptance of its deliverability when 2%/2 mm gamma acceptance criteria are used during the analysis.

Dosimetric and radiobiological comparison for quality assurance of IMRT and VMAT plans.

INTRODUCTION: The gamma analysis used for quality assurance of a complex radiotherapy plan examines the dosimetric equivalence between planned and measured dose distributions within some tolerance. This study explores whether the dosimetric difference is correlated with any radiobiological difference between delivered and planned dose. METHODS: VMAT or IMRT plans optimized for 14 cancer patients were calculated and delivered to a QA device. Measured dose was compared against planned dose using 2-D gamma analysis. Dose volume histograms (for various patient structures) obtained by interpolating measured data were compared against the planned ones using a 3-D gamma analysis. Dose volume histograms were used in the Poisson model to calculate tumor control probability for the treatment targets and in the Sigmoid dose-response model to calculate normal tissue complication probability for the organs at risk. RESULTS: Differences in measured and planned dosimetric data for the patient plans passing at ≥94.9% rate at 3%/3 mm criteria are not statistically significant. Average ± standard deviation tumor control probabilities based on measured and planned data are 65.8±4.0% and 67.8±4.1% for head and neck, and 71.9±2.7% and 73.3±3.1% for lung plans, respectively. The differences in tumor control probabilities obtained from measured and planned dose are statistically insignificant. However, the differences in normal tissue complication probabilities for larynx, lungs-GTV, heart, and cord are statistically significant for the patient plans meeting ≥94.9% passing criterion at 3%/3 mm. CONCLUSION: A ≥90% gamma passing criterion at 3%/3 mm cannot assure the radiobiological equivalence between planned and delivered dose. These results agree with the published literature demonstrating the inadequacy of the criterion for dosimetric QA and suggest for a tighter tolerance.

Clinical radiotherapy application of N-vinylpyrrolidone-containing 3D polymer gel dosimeters with remote external MR-reading.

PURPOSE: Advanced 3D dosimetry is required for verifications of complex dose distributions in modern radiotherapy. Two 3D polymer gel dosimeters, coupled with magnetic resonance (MR) imaging (3 T MRI) readout and data processing with polyGeVero® software, were tested for the verification of calculated 3D dose distributions by a treatment planning system (TPS) and ArcCHECK®-3DVH®, related to eradication of a lung tumour. METHODS: N-vinylpyrrolidone-containing 3D polymer gel dosimeters were used: VIC (containing ascorbic acid and copper sulfate pentahydrate) and VIC-T (containing tetrakis(hydroxymethyl)phosphonium chloride). Three remote centers were involved in the dosimeters preparation and irradiation (Poland), and MRI (Austria). Cross beam calibration of the dosimeters and verification of a 3D dose distribution calculated with an Eclipse External Beam TPS and ArcCHECK®-3DVH® were performed. The 3D-to-3D comparisons of the VIC and VIC-T with TPS and ArcCHECK®-3DVH® along with ArcCHECK®-3DVH® versus TPS dose matrixes were performed with the aid of the polyGeVero® by analyzing dose profiles, isodoses lines, gamma index, gamma angle, dose difference, and related histograms. RESULTS: The measured MR-relaxation rate (R2 = 1/T2) for the dosimeters relates to the dose, as follows: R2 = 0.0928 ± 0.0008 [Gy-1 s-1] × D [Gy] + 2.985 ± 0.012 [s-1] (VIC) and 0.1839 ± 0.0044 [Gy-1 s-1] × D [Gy] + 2.519 ± 0.053 [s-1] (VIC-T). The 3D-to-3D comparisons revealed a good agreement between the measured and calculated 3D dose distributions. CONCLUSIONS: VIC and VIC-T with 3T MRI readout and polyGeVero® showed potential for verifications of calculated irradiation plans. The results obtained suggest the implementation of the irradiation plan for eradication of the lung tumour.

Patient-Specific Quality Assurance Protocol for Volumetric Modulated Arc Therapy using Dose Volume Histogram.

A retrospective study was performed to explore the use of dose volume histogram (DVH) metrics in a patient-specific quality assurance protocol for volumetric modulated arc therapy (VMAT). Fourteen head and neck (HN) and ten brain patients treated with VMAT at the Launceston General Hospital were retrospectively analyzed using the new protocol to identify cases where patient dose errors exceed the established action levels that were not originally detected by either point dose and/or gamma index methods. The Sun Nuclear 3DVH software was used to estimate the dose delivered to the patient volume in terms of DVH dose errors. Thus, three different pretreatment verification methods were used to assess if a plan was considered acceptable. In two particular cases, the dose difference determined with point dose was above the established threshold, although it was found that this was due to the placement of the chamber in the phantom. In all cases, 3DVH confirmed that the dose delivered to target volumes (planning target volume - D50%) and to relevant organs at risk was within prescribed dose tolerances. This study has demonstrated the integration of DVH metrics into a VMAT PSQA protocol to provide clinically meaningful results that complement point dose and gamma index measurements. 3DVH should be regarded as an investigative tool that may be useful in diagnosing the cause of failed plans since it allows dose errors to be related to the patient anatomy.

Validation of the Mobius system for patient-specific quality assurance using introduced intentional errors.

Mobius3D and MobiusFX are model-based verification tools for treatment plan dose calculation and treatment delivery. The software facilitates patient-specific quality assurance by extracting data from linear accelerator treatment log files and performing a 3D dose calculation on the original patient CT dataset using an independent collapsed cone algorithm. In this study, we evaluate the ability of the Mobius system to detect linear accelerator-related errors compared with existing measurement-based systems, namely the ArcCHECK® and 3DVH® systems. Three original treatment plans and 47 plans with introduced delivery errors, for a total of 50 plan deliveries, were investigated. The results from this study demonstrated comparable gamma passing rates and error detectability between the Mobius and ArcCHECK® systems while the 3DVH system generally exhibited a lower sensitivity. This work also demonstrated the ability of the Mobius system to detect delivery errors of down to 2° collimator rotation, 1 mm MLC bank offset and 10 mm collimator jaw offset.

Dosimetric verification of stereotactic body radiotherapy treatment plan via ArcCHECK-3DVH system / 中南大学学报(医学版)

OBJECTIVES@#To study the feasibility of ArcCHECK-3DVH system in dosimetric verification for stereotactic body radiaotherapy (SBRT) with flattening filter free (FFF) model.@*METHODS@#SBRT treatment plans for 57 patients were introduced into ArcCHECK phantom and recalculated. The calculated dose distribution of treatment planning system and the measured dose distribution of ArcCHECK phantom were compared by γ analysis. Then the 3 dimensional dose distribution of target and organs at risk was reconstructed by 3DVH software. The reconstructed dose and calculated dose with treatment planning system (TPS) were compared, and the dose volume γ pass rate and deviation of dose volume parameters to the target and organs at risk were quantitatively valuated.@*RESULTS@#Based on the threshold criteria (3%, 3 mm, 10%), namely the deviation of measuring points between the planned value and the measured value was less than 3%, and the proportion of points with similar values in the plane or sphere with the center of the point and the radius of 3 mm was 10%, the relative and absolute dose pass rates of SBRT treatment plans in ArcCHECK system via γ analysis were greater than 95%. Based on the stricter threshold criteria (2%, 2 mm, 10%), the relative and absolute dose pass rates of SBRT treatment plan in ArcCHECK system via γ analysis were about 93%. In 3DVH dose verification, the γ pass rate of target and organs at risk was exceed 97%, and the deviations in 3DVH of the target and organs at risk were less than ±5%.@*CONCLUSIONS@#The ArcCHECK-3DVH system in dose verification can provide more comprehensive dose distribution information to reasonably evaluate the SBRT plan, with more significance for guiding clinical treatment.

Initial experience of ArcCHECK and 3DVH software for RapidArc treatment plan verification.

The purpose of this study was to perform delivery quality assurance with ArcCHECK and 3DVH system (Sun Nuclear, FL) and to evaluate the suitability of this system for volumetric-modulated arc therapy (VMAT) (RapidArc [RA]) verification. This software calculates the delivered dose distributions in patients by perturbing the calculated dose using errors detected in fluence or planar dose measurements. The device is tested to correlate the gamma passing rate (%GP) and the composite dose predicted by 3DVH software. A total of 28 patients with prostate cancer who were treated with RA were analyzed. RA treatments were delivered to a diode array phantom (ArcCHECK), which was used to create a planned dose perturbation (PDP) file. The 3DVH analysis used the dose differences derived from comparing the measured dose with the treatment planning system (TPS)-calculated doses to perturb the initial TPS-calculated dose. The 3DVH then overlays the resultant dose on the patient's structures using the resultant "PDP" beams. Measured dose distributions were compared with the calculated ones using the gamma index (GI) method by applying the global (Van Dyk) normalization and acceptance criteria, i.e., 3%/3mm. Paired differences tests were used to estimate statistical significance of the differences between the composite dose calculated using 3DVH and %GP. Also, statistical correlation by means of logistic regression analysis has been analyzed. Dose-volume histogram (DVH) analysis for patient plans revealed small differences between treatment plan calculations and 3DVH results for organ at risk (OAR), whereas planning target volume (PTV) of the measured plan was systematically higher than that predicted by the TPS. The t-test results between the planned and the estimated DVH values showed that mean values were incomparable (p < 0.05). The quality assurance (QA) gamma analysis 3%/3mm showed that in all cases there were only weak-to-moderate correlations (Pearson r: 0.12 to 0.74). Moreover, clinically relevant differences increased with increasing QA passing rate, indicating that some of the largest dose differences occurred in the cases of high QA passing rates, which may be called "false negatives." The clinical importance of any disagreement between the measured and the calculated dose is often difficult to interpret; however, beam errors (either in delivery or in TPS calculation) can affect the effectiveness of the patient dose. Further research is needed to determinate the role of a PDP-type algorithm to accurately estimate patient dose effect.

Dosimetric evaluation of MapCHECK 2 and 3DVH in the IMRT delivery quality assurance process.

Based on per-field data, 3 dose-volume histogram (DVH) is designed to calculate 3-dimensional (3D) dose using patient-computed tomography (CT) for an intensity-modulated radiation therapy (IMRT) delivery quality assurance (DQA) process measured with diode detector arrays. In this study, the characteristics and suitability of 3DVH for an IMRT DQA process were evaluated by assessment of clinically applied results. The DQA plans were prepared with a 2D diode detector array (MapCHECK 2) for 20 IMRT patients (10 with head and neck cancer and 10 with prostate cancer), and the matching rate between the calculated dose and the measured dose was analyzed. The relative dose differences between the original IMRT plan and the recalculated plan by 3DVH were evaluated for tumor target and organs at risk (OARs). Confidence limits (CLs) were determined for quantification of the degree of agreement that should be expected in each DQA method. The individual CLs for DQA accuracy of 3D dosimetric evaluation in the tumor target and OARs were also calculated to evaluate the differences compared with conventional 2D-based DQA results. The matching rates were sufficient to validate the accuracy of IMRT DQA analyses and the calculated CL values were reasonable values considering the normal criteria of our institution. The 3DVH analysis generally had better matching rate than per-field measurement analysis and the CL values for OARs were better than those for the planning target volume (PTV). The usefulness of the 3DVH tool was verified for IMRT DQA from the point of view of dose evaluation in the corresponding patient's CT data. It also enables dosimetric evaluation in each important structure (PTV and OARs), which can promote more effective evaluation of DQA error in terms of tumor treatment and side effects.